https://assets.capyfin.com/instruments/678fdc13234e27009c5d5ac1.png avatar
Exact Sciences
🇺🇸 NASDAQ:EXAS
View Company
OverviewEarningsDividends
•
Jun 30, 2024

Exact Sciences Q2 2024 Earnings Report

Achieved record results, screened over 1 million people with Cologuard, and raised adjusted EBITDA guidance.

Key Takeaways

Exact Sciences Corp. announced strong second-quarter results, with a 12% increase in total revenue to $699 million. The company screened over 1 million people with Cologuard for the first time in a quarter and advanced its pipeline. Full-year revenue guidance was maintained, and adjusted EBITDA guidance was raised.

Total second quarter revenue was $699 million, a 12% increase year-over-year.

Screening revenue reached $532 million, a 15% increase year-over-year.

Precision Oncology revenue was $168 million, a 7% increase year-over-year.

Adjusted EBITDA was $110 million, with an adjusted EBITDA margin of 16%.

Total Revenue
$699M
Previous year: $622M
+12.4%
EPS
-$0.09
Previous year: -$0.45
-80.0%
Gross Margin
70%
Previous year: 71%
-1.4%
Adjusted EBITDA
$110M
Previous year: $66.9M
+64.5%
Gross Profit
$488M
Previous year: $444M
+9.9%
Cash and Equivalents
$530M
Previous year: $604M
-12.3%
Free Cash Flow
$71.2M
Previous year: $65.7M
+8.4%
Total Assets
$6.67B
Previous year: $6.36B
+5.0%

Exact Sciences

Exact Sciences

Exact Sciences Revenue by Segment

Forward Guidance

The company maintained its full-year 2024 revenue guidance and raised its full-year 2024 adjusted EBITDA guidance.

Revenue & Expenses

Visualization of income flow from segment revenue to net income

Company Overview

Full financial data and analysis

View Exact Sciences